BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36776299)

  • 1. The biological impacts of CEBPD on urothelial carcinoma development and progression.
    Chan TC; Shiue YL; Li CF
    Front Oncol; 2023; 13():1123776. PubMed ID: 36776299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.
    Chan TC; Hsing CH; Shiue YL; Huang SK; Hsieh KL; Kuo YH; Li CF
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis.
    Chan TC; Chen YT; Tan KT; Wu CL; Wu WJ; Li WM; Wang JM; Shiue YL; Li CF
    Clin Transl Med; 2021 Dec; 11(12):e674. PubMed ID: 34954904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.
    Wang YH; Wu WJ; Wang WJ; Huang HY; Li WM; Yeh BW; Wu TF; Shiue YL; Sheu JJ; Wang JM; Li CF
    Oncotarget; 2015 Oct; 6(31):31069-84. PubMed ID: 26307680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
    Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
    J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
    Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    Liang PI; Lai HY; Chan TC; Li WM; Hsing CH; Huang SK; Hsieh KL; Tseng WH; Chen TJ; Li WS; Chen HD; Kuo YH; Li CF
    BMC Cancer; 2023 Jun; 23(1):599. PubMed ID: 37380971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder.
    Lee YY; Wang CT; Huang SK; Wu WJ; Huang CN; Li CC; Chan TC; Liang PI; Hsing CH; Li CF
    J Cancer; 2016; 7(15):2187-2196. PubMed ID: 27994654
    [No Abstract]   [Full Text] [Related]  

  • 10. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
    Chan TC; Wu WJ; Li WM; Shiao MS; Shiue YL; Li CF
    Theranostics; 2020; 10(25):11775-11793. PubMed ID: 33052246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells.
    Hour TC; Lai YL; Kuan CI; Chou CK; Wang JM; Tu HY; Hu HT; Lin CS; Wu WJ; Pu YS; Sterneck E; Huang AM
    Biochem Pharmacol; 2010 Aug; 80(3):325-34. PubMed ID: 20385105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.
    Lee HY; Yeh BW; Chan TC; Yang KF; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Liang PI; Shiue YL; Wu WJ; Li CF
    Oncotarget; 2017 Jul; 8(29):47216-47229. PubMed ID: 28525382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer.
    Zhou Y; Liu F; Xu Q; Yang B; Li X; Jiang S; Hu L; Zhang X; Zhu L; Li Q; Zhu X; Shao H; Dai M; Shen Y; Ni B; Wang S; Zhang Z; Teng Y
    Oncogene; 2020 Aug; 39(34):5633-5648. PubMed ID: 32661323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.
    Lee YY; Wu WJ; Huang CN; Li CC; Li WM; Yeh BW; Liang PI; Wu TF; Li CF
    J Cancer; 2016; 7(6):711-21. PubMed ID: 27076853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of Cartilage Oligomeric Matrix Protein Predicts Poor Prognosis in Urothelial Carcinoma.
    Kuo YH; Lai HY; Chan TC; Hsing CH; Huang SK; Hsieh KL; Chen TJ; Li WS; Lu JC; Li CF
    Onco Targets Ther; 2022; 15():727-740. PubMed ID: 35795328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis.
    Lai HY; Chiu CC; Kuo YH; Tsai HH; Wu LC; Tseng WH; Liu CL; Hsing CH; Huang SK; Li CF
    Front Oncol; 2022; 12():834249. PubMed ID: 35372028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract.
    Lee HY; Li CC; Huang CN; Li WM; Yeh HC; Ke HL; Yang KF; Liang PI; Li CF; Wu WJ
    J Surg Oncol; 2015 Mar; 111(4):414-22. PubMed ID: 25488476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
    Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
    Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.
    Yang Y; Xia S; Zhang L; Wang W; Chen L; Zhan W
    Cancer Biol Ther; 2020 Jun; 21(6):522-532. PubMed ID: 32151175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.